Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥18 years of age.~* Histologically confirmed diagnosis of a solid tumor malignancy documented by cytology or biopsy.~* Presence of metastatic disease.~* Hemoglobin value between ≥8.0 to \<11.0 g/dL (≥80 to \<110 g/L).~* ≥28 days must have elapsed (prior to pre-dose red blood cell mass / plasma volume test) since previous treatment with erythropoiesis-stimulating agent (including concurrent treatment with intravenous \[IV\] iron).~* ≥28 days must have elapsed (prior to Day 1) since the last red blood cell transfusion and receipt of ≤2 units of blood in the past 56 days (prior to Day 1).~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 1.~Exclusion Criteria:~At the time of screening, participants who have any grade ≥3 toxicity (according to the currently active minor version of NCI CTCAE v4.0) except for the following disease-related toxicities:~* Hematological events - anemia, thrombocytopenia, neutropenia~* Non-hematological events - nausea, vomiting, fatigue, muscle or bone/joint pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sotatercept (Type: EXPERIMENTAL): Participants will receive a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.

Based on this trial design, predict the completion outcome and termination type (if applicable).